Beximco Pharmaceuticals Ltd (LON:BXP) (Dhaka:BXPH.DH), a pharmaceutical company in Bangladesh, will start selling a generic version of Merck & Co's (NYSE:MRK) antiviral pill for COVID-19 following local regulatory approval, Reuters news agency reported on Tuesday.
The company stated that it will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it had received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration.
This marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir.
Molnupiravir had received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.
Beximco added that exports would depend on regulatory approvals globally.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval